secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspire Biopharma Holdings, Inc. (ASBP)
CIK:        0001847345
Form:       8-K
Filed at:   2026-06-12T14:26:16+00:00
Accession:  0001493152-26-028386
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aspire Biopharma signs $30M cash deal for auto supplier DCS with >$200M revenue
-------------------------------------------------------------------------------

- DCS generated >$200M revenue, >$22M Adjusted EBITDA, >$17M net income in FY2025 (unaudited).
- Purchase price $30M cash; no new equity financing expected; closing targeted Q3 2026.
- DCS operates 11 global facilities, holds 310+ patents, serves 150+ vehicle platforms and blue-chip OEMs.
- Existing DCS CEO Hans Vorstenbosch continues; leadership bolstered by Lakewood & Company with 200+ years experience.
- Acquisition transforms Aspire into diversified high-revenue enterprise while advancing drug delivery technology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847345/000149315226028386/0001493152-26-028386-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847345/000149315226028386/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-028386

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer